The Risk Of Developing Anemia In Patients With Chronic Heart Failure And Its Prognostic Value
Keywords:
Abstract
Analysis of modern views on the problem of anemia in chronic heart failure (CHF), on the main pathogenetic mechanisms of its formation and the possibility of drug correction. The CHF problem has a number of interdisciplinary aspects. One of the pathologies often encountered in CHF is anemia, which aggravates hemodynamic disturbances and worsens the prognosis in patients. Understanding the mechanisms of the development of anemia in CHF is of great importance for the choice of treatment tactics. The review discusses the views on the pathogenetic mechanisms of the formation of anemic syndrome in patients with CHF. The approaches to its treatment from the point of view of pathogenesis are considered. Anemia in CHF is associated with an increased risk of death, worsening of the course of concomitant diseases and an increase in the functional class of heart failure, but it is a potentially reversible condition.
Similar Articles
-
HORMONAL FUNCTION OF ADENOHYPOPHISIS
The American Journal of Medical Sciences and Pharmaceutical Research: No. 02 (2022) / Sadik Tursunovich Khudaiberdiev,
References
Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J. S. et al. Rekomendatsii ESK po diagnostike i lecheniyu ostroi i khronicheskoi serdechnoi nedostatochnosti 2016. Ros. kardiol. zhurn. 2017; 1(141): 7–81. (in Russian)
Solomakhina N.I., Nakhodnova E.S., Ershov V.I. Anemiya pri khronicheskoi serdechnoi nedostatochnosti: rol' gepsidina kak universal'nogo regulyatora metabolizma zheleza. Zhurn. Serdech. Nedostatochnost'. 2014; 85(4): 254–60. (in Russian)]
Marazia S., Loderini S., Magliari F., Sarullo F.M., Di Mauro M. Sucrosomial iron supplementation can be a useful support treatment in patients with heart failure and anemia. In: Materials of 5th International Multidisciplinary Course on Iron Anemia. Florence, Italy. March 31 — April 1, 2017.
Zakhidova K.Kh. Vybor optimal'noi terapii pri korrektsii anemicheskogo sindroma u bol'nykh s khronicheskoi serdechnoi nedostatochnost'yu. Kardiologiya. 2018; 58(1): 25–31. (in Russian)
Stuklov N.I. Defitsit zheleza i anemiya u bol'nykh khronicheskoi serdechnoi nedostatochnost'yu. Ratsion. farmakoterapiya v kardiologii. 2017; 13(5): 651–60. (in Russian)
Rudakova L.E., Belyaeva Yu.B., Fatkabrarova A.M., Kozina L.E. Anemiya pri khronicheskoi serdechnoi nedostatochnosti (po dannym kardiologicheskogo otdeleniya). Teoret. i priklad. aspekty sovrem. nauki. 2014; 6(2): 128–30. (in Russian)
Andreichev L.A., Baleeva L.V. Anemiya khronicheskikh zabolevanii. Rus. med. zhurn. 2014; 2: 50–5. (in Russian)
Ebner N., Jankowska E.A., Ponikowski P., Lainscak M., Elsner S., Sliziuk V. et al. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure. Int. J. Cardiol. 2016; 205: 6–12. DOI: 10.1016/j.ijcard.2015.11.178
Rukavitsyn O.A. Anemiya khronicheskikh zabolevanii: otdel'nye aspekty patogeneza i puti korrektsii. Onkogematologiya. 2016; 11(1): 37–46. (in Russian)
Caughey M.C., Avery C.L., Ni H., Solomon S.D., Matsushita K., Wruck L.M. et al. Outcomes of patients with anemia and acute decompensated heart failure with preserved versus reduced ejection fraction (from the ARIC study community surveillance). Am. J. Cardiol. 2014; 114(12): 1850–4. DOI: 10.1016/j.amjcard.2014.09.024
Sharova E.K., Babaeva L.A., Padaryan S.S., Soseliya N.N., Lukina O.I., Mil'to A.S. Khronicheskaya serdechnaya nedostatochnost': rekomendatsii i real'naya klinicheskaya praktika. Ratsion. farmakoterapiya v kardiologii. 2016; 12(6): 631–7. (in Russian)
Yusuf S., Pitt B., Davis C.E., Hood W.B., Cohn J.N. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 1991; 325(5): 293–302. DOI: 10.1056/NEJM199108013250501
Silverberg D.S., Wexler D., Blum M., Tchebiner J.Z., Sheps D., Keren G. et al. The effect of correction of anaemia in diabetics and non¬diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol. Dial. Transplant. 2003; 18(1): 141–6.
Martirosyan N.V., Tazhenova N.N., Demidov A.A. Dinamika klinicheskikh pokazatelei u bol'nykh khronicheskoi serdechnoi nedostatochnost'yu pozhilogo vozrasta s anemiei v zavisimosti ot lecheniya. Mezhdunar. zhurn. priklad. i fundamental. issledovanii. 2015; 12: 827–9. (in Russian)
Alexander M., Grumbach K., Remy L., Rowell R., Massie B.M. Congestive heart failure hospitalizations and survival in California: patterns according to race/ethnicity. Am. Heart J. 1999; 137(5): 919–27.
Akimova A.V., Nevskaya A.V., Milashchenko A.I., Kondrashova E.V. Osobennosti anemii khronicheskikh zabolevanii v terapevticheskom statsionare. Vestn. ural. med. akad. nauki. 2018; 15(1): 5–11. (in Russian)
Kalra P.R., Collier T., Cowie M.R., Fox K.F., Wood D.A., PooleWilson P.A. et al. Haemoglobin concentration and prognosis in new cases of heart failure. Lancet. 2003; 362(9379): 211–2. DOI: 10.1016/S0140-6736(03)13912-8
Ezekowitz J.A., McAlister F.A., Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohortof 12 065 patients with new¬onset heart failure. Circulation. 2003; 107(2): 223–5.
Ivanov V.P., Kolesnik M.O., Kolesnik O.M., Ivanova E.I. Osoblivosti perebigu khronichnoї sertsevoї nedostatnosti z komorbidnim zalizodefitsitom, kliniko-prognostichne znachennya korektsiї zalizodefitsitu Kardiologiya: ot nauki k praktike. 2015; 3(16): 61–85. (in Ukrainian)
Arutyunov G.P. Anemiya u bol'nykh s KhSN. Zhurn. Serdech. Nedostatochnost'. 2003; 5: 224–8. (in Russian)
Nemeth E., Preza G.C., Jung C.L., Kaplan J., Waring A.J., Ganz T. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-functionstudy. Blood. 2006; 107(1): 328–33. DOI: 10.1182/blood-2005-05-2049
Shcherbinina S.P., Levina A.A., Lisovskaya I.L., Attaullakhanov F.I. Deistvie ekzogennykh antioksidantov na antiokislitel'nyi status eritrotsitov i uroven' gepsidina v krovi bol'nykh s narusheniyami regulyatsii metabolizma zheleza. Biomed. khimiya. 2013; 6: 710–8. (in Russian
Ganz T. Hepcidin in iron metabolism. Curr. Opin. Hematol. 2004; 11(4): 251–4.
Meshcheryakova L.M., Levina M.M., Tsybul'skaya A.A., Tret'yakov A.A., Suvorova N.N Osobennosti pokazatelei obmena zheleza (gepsidina, ferritina, HIF) pri smeshannykh anemiyakh. V sb. nauch. trudov: Tendentsii razvitiya nauki i obrazovaniya. Po materialam XXVII mezhdunar. nauch.-prakt. konferentsii. Samara, 30 iyunya 2017 g. Samara: L-Zhurnal; 2017. Chast' 1. (in Russian)
Khrutskaya M.S. Kliniko-patogeneticheskie aspekty anemicheskogo sindroma u patsientov s khronicheskoi serdechnoi nedostatochnost'yu. V pomoshch' praktich. vrachu. 2014; 3: 134–8. (in Russian)
Bugrova I.A., Kalyuta T.Yu., Korsunova E.N., Shvarts Yu.G. Otkloneniya pokazatelei krasnoi krovi u patsientov s serdechno-sosudistymi zabolevaniyami — epidemiologiya, prognoz i podkhody k lecheniyu. Kardiovaskulyar. terapiya i profilaktika. 2014; 13(6): 62–7. (in Russian)
Kravchun P.G., Efremova O.A., Ryndina N.G., Titova A.Yu. Struktura anemicheskogo sindroma i osobennosti trofologicheskogo statusa u bol'nykh s khronicheskoi serdechnoi nedostatochnost'yu i khronicheskoi bolezn'yu pochek. Nauch. vedomosti BelGU. 2013; 11(154): 102–6. (in Russian)
Matsumoto M., Tsujino T., Lee-Kawabata M., Naito Y., Akahori H., Sakoda T. et al. Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia. Circ. J. 2010; 74(2): 301–6.
Enjuanes C., Klip I.T., Bruguera J., Cladellas M., Ponikowski P., Banasiak W. et al. Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenterEuropean study. Int. J. Cardiol. 2014; 174(2): 268–75. DOI: 10.1016/j.ijcard.2014.03.169
Enjuanes C., Bruguera J., Grau M., Cladellas M., Gonzalez G., Meroño O. et al. Iron status in chronic heart failure: impact on symptoms, functional class and submaximal exercise capacity. Rev. Esp. Cardiol. (Engl. ed.). 2016; 69(3): 247–55. DOI: 10.1016/j.rec.2015.08.018
